Table 2.

Association of baseline characteristics and clinical outcomes

CharacteristicNo.OSDFSRelapseNRM
HR*95% CIP*HR*95% CIP*HR†95% CIP†HR†95% CIP†
Age at diagnosis, y              
 <55 55 Ref  .71 Ref  .96 Ref  .32 Ref  .48 
 55-65 43 1.20 0.62-2.31  0.92 0.50-1.69  0.51 0.18-1.43  1.47 0.66-3.25  
 >65 12 1.46 0.54-3.92  0.97 0.37-2.54  0.38 0.05-3.04  1.76 0.62-5.00  
Age at allo-HCT, y              
 <55 38 Ref  .24 Ref  .88 Ref  .30 Ref  .14 
 55-65 51 1.60 0.77-3.33  1.13 0.59-2.16  0.46 0.16-1.28  2.36 0.90-6.16  
 >65 21 2.03 0.83-4.95  1.22 0.53-2.81  0.56 0.16-2.00  2.37 0.75-7.44  
Years from diagnosis to HCT              
 <1 47 Ref  .71 Ref  .60 Ref  .63 Ref  .63 
 1 to <3 29 0.72 0.33-1.58  0.71 0.35-1.46  0.86 0.29-2.54  0.65 0.25-1.72  
 3+ 34 0.91 0.45-1.87  0.80 0.40-1.57  0.57 0.18-1.81  1.00 0.44-2.26  
Sex              
 Male 65 Ref  .071 Ref  .065 Ref  .20 Ref  .26 
 Female 45 0.54 0.28-1.07  0.56 0.30-1.05  0.52 0.19-1.45  0.64 0.29-1.41  
Year of allo-HCT              
 2004-2011 56 Ref  .71 Ref  .53 Ref  .41 Ref  .98 
 2012-2017 54 1.12 0.58-2.17  0.83 0.45-1.54  0.67 0.26-1.70  0.92 0.43-1.97  
Female donor to male recipient              
 Yes 18 Ref  .23 Ref  .53 Ref  .97 Ref  .47 
 No 92 0.64 0.30-1.35  0.79 0.38-1.65  0.97 0.28-3.35  0.72 0.31-1.70  
ABO compatibility              
 Compatible 61 Ref  .61 Ref  .97 Ref  .50 Ref  .52 
 Minor 18 0.85 0.32-2.26  1.08 0.47-2.52  2.02 0.68-5.94  0.44 0.10-1.88  
 Major 20 1.51 0.69-3.28  1.17 0.55-2.51  1.01 0.28-3.68  1.22 0.48-3.08  
 Bidirectional 11 1.44 0.54-3.85  1.17 0.45-3.06  0.57 0.08-4.29  1.56 0.53-4.59  
Donor type              
 Related 51 Ref  .001 Ref  .002 Ref  .12 Ref  <.001 
 MUD 10/10 44 1.46 0.72-2.95  2.35 1.21-4.55  2.33 0.87-6.21  1.77 0.76-4.14  
 <10/10 15 3.96 1.76-8.88  3.64 1.63-8.15  0.57 0.07-4.90  5.64 2.20-14.45  
DIPSS classification at allo-HCT              
 Low-intermediate-1 26 Ref  .023 Ref  .035 Ref  .16 Ref  .22 
 Intermediate-2 to high 83 2.60 1.09-6.18  2.18 1.01-4.70  2.69 0.62-11.66  1.65 0.70-3.91  
Recipient CMV              
 Negative 19 Ref  .46 Ref  .89 Ref  .98 Ref  .86 
 Positive 91 1.39 0.58-3.30  1.06 0.49-2.26  1.02 0.29-3.55  1.07 0.41-2.83  
Donor CMV              
 Negative 49 Ref  .25 Ref  .18 Ref  .65 Ref  .28 
 Positive 60 0.70 0.38-1.30  0.68 0.38-1.21  0.81 0.32-2.02  0.70 0.34-1.43  
KPS              
 90-100 46 Ref  .36 Ref  .43 Ref  .057 Ref  .65 
 70-80 37 1.45 0.71-2.94  1.39 0.70-2.77  1.95 0.56-6.78  1.07 0.46-2.48  
 Unknown 27 0.86 0.37-1.97  1.54 0.75-3.17  3.96 1.21-12.99  0.74 0.29-1.88  
HCT-CI              
 0 38 Ref  .59 Ref  .41 Ref  .085 Ref  .73 
 1 26 1.48 0.65-3.37  1.47 0.65-3.33  1.97 0.45-8.60  1.20 0.46-3.13  
 2 21 1.51 0.61-3.73  1.68 0.71-3.98  1.89 0.38-9.33  1.43 0.51-4.04  
 Unknown 25 0.96 0.40-2.28  1.85 0.85-4.02  4.70 1.25-17.60  0.88 0.33-2.38  
MF              
 Primary 58 Ref  .29 Ref  .13 Ref  .77 Ref  .19 
 Secondary 52 0.72 0.39-1.34  0.64 0.36-1.15  0.87 0.35-2.19  0.61 0.29-1.27  
Ruxolitinib use              
 No 78 Ref  .33 Ref  .96 Ref  .26 Ref  .35 
 Yes 32 1.39 0.68-2.86  0.98 0.49-1.96  0.49 0.14-1.73  1.40 0.61-3.22  
Splenectomy before HCT              
 No 94 Ref  .24 Ref  .82 Ref  .015 Ref  .062 
 Yes 16 0.58 0.23-1.50  1.09 0.50-2.37  3.31 1.28-8.60  0.31 0.07-1.38  
Cytogenetics              
 Favorable 67 Ref  .006 Ref  .004 Ref  .035 Ref  .23 
 Unfavorable 24 1.80 0.84-3.86  1.29 0.62-2.69  0.54 0.12-2.46  1.80 0.75-4.34  
 VHR 15 3.11 1.48-6.53  3.00 1.49-6.04  2.95 1.11-7.82  1.99 0.81-4.90  
CharacteristicNo.OSDFSRelapseNRM
HR*95% CIP*HR*95% CIP*HR†95% CIP†HR†95% CIP†
Age at diagnosis, y              
 <55 55 Ref  .71 Ref  .96 Ref  .32 Ref  .48 
 55-65 43 1.20 0.62-2.31  0.92 0.50-1.69  0.51 0.18-1.43  1.47 0.66-3.25  
 >65 12 1.46 0.54-3.92  0.97 0.37-2.54  0.38 0.05-3.04  1.76 0.62-5.00  
Age at allo-HCT, y              
 <55 38 Ref  .24 Ref  .88 Ref  .30 Ref  .14 
 55-65 51 1.60 0.77-3.33  1.13 0.59-2.16  0.46 0.16-1.28  2.36 0.90-6.16  
 >65 21 2.03 0.83-4.95  1.22 0.53-2.81  0.56 0.16-2.00  2.37 0.75-7.44  
Years from diagnosis to HCT              
 <1 47 Ref  .71 Ref  .60 Ref  .63 Ref  .63 
 1 to <3 29 0.72 0.33-1.58  0.71 0.35-1.46  0.86 0.29-2.54  0.65 0.25-1.72  
 3+ 34 0.91 0.45-1.87  0.80 0.40-1.57  0.57 0.18-1.81  1.00 0.44-2.26  
Sex              
 Male 65 Ref  .071 Ref  .065 Ref  .20 Ref  .26 
 Female 45 0.54 0.28-1.07  0.56 0.30-1.05  0.52 0.19-1.45  0.64 0.29-1.41  
Year of allo-HCT              
 2004-2011 56 Ref  .71 Ref  .53 Ref  .41 Ref  .98 
 2012-2017 54 1.12 0.58-2.17  0.83 0.45-1.54  0.67 0.26-1.70  0.92 0.43-1.97  
Female donor to male recipient              
 Yes 18 Ref  .23 Ref  .53 Ref  .97 Ref  .47 
 No 92 0.64 0.30-1.35  0.79 0.38-1.65  0.97 0.28-3.35  0.72 0.31-1.70  
ABO compatibility              
 Compatible 61 Ref  .61 Ref  .97 Ref  .50 Ref  .52 
 Minor 18 0.85 0.32-2.26  1.08 0.47-2.52  2.02 0.68-5.94  0.44 0.10-1.88  
 Major 20 1.51 0.69-3.28  1.17 0.55-2.51  1.01 0.28-3.68  1.22 0.48-3.08  
 Bidirectional 11 1.44 0.54-3.85  1.17 0.45-3.06  0.57 0.08-4.29  1.56 0.53-4.59  
Donor type              
 Related 51 Ref  .001 Ref  .002 Ref  .12 Ref  <.001 
 MUD 10/10 44 1.46 0.72-2.95  2.35 1.21-4.55  2.33 0.87-6.21  1.77 0.76-4.14  
 <10/10 15 3.96 1.76-8.88  3.64 1.63-8.15  0.57 0.07-4.90  5.64 2.20-14.45  
DIPSS classification at allo-HCT              
 Low-intermediate-1 26 Ref  .023 Ref  .035 Ref  .16 Ref  .22 
 Intermediate-2 to high 83 2.60 1.09-6.18  2.18 1.01-4.70  2.69 0.62-11.66  1.65 0.70-3.91  
Recipient CMV              
 Negative 19 Ref  .46 Ref  .89 Ref  .98 Ref  .86 
 Positive 91 1.39 0.58-3.30  1.06 0.49-2.26  1.02 0.29-3.55  1.07 0.41-2.83  
Donor CMV              
 Negative 49 Ref  .25 Ref  .18 Ref  .65 Ref  .28 
 Positive 60 0.70 0.38-1.30  0.68 0.38-1.21  0.81 0.32-2.02  0.70 0.34-1.43  
KPS              
 90-100 46 Ref  .36 Ref  .43 Ref  .057 Ref  .65 
 70-80 37 1.45 0.71-2.94  1.39 0.70-2.77  1.95 0.56-6.78  1.07 0.46-2.48  
 Unknown 27 0.86 0.37-1.97  1.54 0.75-3.17  3.96 1.21-12.99  0.74 0.29-1.88  
HCT-CI              
 0 38 Ref  .59 Ref  .41 Ref  .085 Ref  .73 
 1 26 1.48 0.65-3.37  1.47 0.65-3.33  1.97 0.45-8.60  1.20 0.46-3.13  
 2 21 1.51 0.61-3.73  1.68 0.71-3.98  1.89 0.38-9.33  1.43 0.51-4.04  
 Unknown 25 0.96 0.40-2.28  1.85 0.85-4.02  4.70 1.25-17.60  0.88 0.33-2.38  
MF              
 Primary 58 Ref  .29 Ref  .13 Ref  .77 Ref  .19 
 Secondary 52 0.72 0.39-1.34  0.64 0.36-1.15  0.87 0.35-2.19  0.61 0.29-1.27  
Ruxolitinib use              
 No 78 Ref  .33 Ref  .96 Ref  .26 Ref  .35 
 Yes 32 1.39 0.68-2.86  0.98 0.49-1.96  0.49 0.14-1.73  1.40 0.61-3.22  
Splenectomy before HCT              
 No 94 Ref  .24 Ref  .82 Ref  .015 Ref  .062 
 Yes 16 0.58 0.23-1.50  1.09 0.50-2.37  3.31 1.28-8.60  0.31 0.07-1.38  
Cytogenetics              
 Favorable 67 Ref  .006 Ref  .004 Ref  .035 Ref  .23 
 Unfavorable 24 1.80 0.84-3.86  1.29 0.62-2.69  0.54 0.12-2.46  1.80 0.75-4.34  
 VHR 15 3.11 1.48-6.53  3.00 1.49-6.04  2.95 1.11-7.82  1.99 0.81-4.90  

HCT-CI, hematopoietic cell transplantation–specific comorbidity index; KPS, Karnofsky performance status; Ref, reference.

*

Based on univariable analysis and log-rank test.

†

Based on cumulative incidence accounting for competing risks and Gray test.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal